NYSE:QGEN (Netherlands)
Business Description
Qiagen NV
NAICS : 541720
SIC : 8733
Hulsterweg 82, Venlo, NLD, 5912 PL
Description
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (45% of 2021 sales), followed by EMEA (36%) and Asia-Pacific (19%).
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.68 | |||||
| Equity-to-Asset | 0.53 | |||||
| Debt-to-Equity | 0.59 | |||||
| Debt-to-EBITDA | 2.18 | |||||
| Interest Coverage | 12.12 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.7 | |||||
| Beneish M-Score | -2.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.7 | |||||
| 3-Year EBITDA Growth Rate | 21.7 | |||||
| 3-Year EPS without NRI Growth Rate | 39.2 | |||||
| 3-Year FCF Growth Rate | 27.8 | |||||
| 3-Year Book Growth Rate | 5.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 4.85 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | -0.68 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.63 | |||||
| 9-Day RSI | 39.7 | |||||
| 14-Day RSI | 46.31 | |||||
| 6-1 Month Momentum % | -4.59 | |||||
| 12-1 Month Momentum % | -9.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.23 | |||||
| Quick Ratio | 1.89 | |||||
| Cash Ratio | 1.36 | |||||
| Days Inventory | 149.69 | |||||
| Days Sales Outstanding | 57.95 | |||||
| Days Payable | 42.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.2 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 64.44 | |||||
| Operating Margin % | 29.06 | |||||
| Net Margin % | 22.75 | |||||
| ROE % | 16.47 | |||||
| ROA % | 8.45 | |||||
| ROIC % | 11.63 | |||||
| ROC (Joel Greenblatt) % | 69.88 | |||||
| ROCE % | 13.41 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 21.32 | |||||
| Forward PE Ratio | 21.59 | |||||
| PE Ratio without NRI | 21.32 | |||||
| Shiller PE Ratio | 55.92 | |||||
| Price-to-Owner-Earnings | 22.13 | |||||
| PEG Ratio | 1.04 | |||||
| PS Ratio | 4.84 | |||||
| PB Ratio | 3.29 | |||||
| Price-to-Tangible-Book | 31.12 | |||||
| Price-to-Free-Cash-Flow | 19.81 | |||||
| Price-to-Operating-Cash-Flow | 14.9 | |||||
| EV-to-EBIT | 16.71 | |||||
| EV-to-Forward-EBIT | 19.41 | |||||
| EV-to-EBITDA | 12.81 | |||||
| EV-to-Forward-EBITDA | 14.82 | |||||
| EV-to-Revenue | 5.05 | |||||
| EV-to-Forward-Revenue | 5.35 | |||||
| EV-to-FCF | 20.95 | |||||
| Price-to-Projected-FCF | 1.97 | |||||
| Price-to-Median-PS-Value | 0.93 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.91 | |||||
| Price-to-Graham-Number | 5.42 | |||||
| Earnings Yield (Greenblatt) % | 5.99 | |||||
| Forward Rate of Return (Yacktman) % | 22.19 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NYSE:QGEN
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,261.046 | ||
| EPS (TTM) ($) | 2.22 | ||
| Beta | 0.19 | ||
| Volatility % | 19.91 | ||
| 14-Day RSI | 46.31 | ||
| 14-Day ATR ($) | 1.002164 | ||
| 20-Day SMA ($) | 49.1005 | ||
| 12-1 Month Momentum % | -9.83 | ||
| 52-Week Range ($) | 41.32 - 58 | ||
| Shares Outstanding (Mil) | 227.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Qiagen NV Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||